PubRank

Joshua R Korzenik

Author PubWeight™ 48.07‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004 6.77
2 A prospective study of long-term intake of dietary fiber and risk of Crohn's disease and ulcerative colitis. Gastroenterology 2013 4.06
3 Higher predicted vitamin D status is associated with reduced risk of Crohn's disease. Gastroenterology 2011 3.84
4 Risks and benefits of infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol 2006 2.88
5 Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor. Lancet 2002 2.74
6 LRRK2 is involved in the IFN-gamma response and host response to pathogens. J Immunol 2010 1.85
7 Non-invasive mapping of the gastrointestinal microbiota identifies children with inflammatory bowel disease. PLoS One 2012 1.66
8 Dysregulation of Reg gene expression occurs early in gastrointestinal tumorigenesis and regulates anti-apoptotic genes. Cancer Biol Ther 2006 1.63
9 Probiotics to minimize the disruption of faecal microbiota in healthy subjects undergoing antibiotic therapy. J Med Microbiol 2009 1.58
10 Transition of adolescents with inflammatory bowel disease from pediatric to adult care: a survey of adult gastroenterologists. J Pediatr Gastroenterol Nutr 2009 1.22
11 Physical activity and risk of inflammatory bowel disease: prospective study from the Nurses' Health Study cohorts. BMJ 2013 1.18
12 Association of glycogen storage disease 1b and Crohn disease: results of a North American survey. Eur J Pediatr 2002 1.11
13 Probiotics for recurrent Clostridium difficile disease. J Med Microbiol 2005 1.06
14 Impact of coexistent celiac disease on phenotype and natural history of inflammatory bowel diseases. Am J Gastroenterol 2013 1.05
15 Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort. Inflamm Bowel Dis 2015 0.99
16 Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease. Gut 2011 0.97
17 Chemical and cytokine features of innate immunity characterize serum and tissue profiles in inflammatory bowel disease. Proc Natl Acad Sci U S A 2013 0.97
18 Analysis of treatment effects on the microbial ecology of the human intestine. FEMS Microbiol Ecol 2006 0.96
19 Inflammatory bowel disease and environmental influences. Gastroenterol Clin North Am 2002 0.95
20 Can mucosal healing be a cost-effective endpoint for biologic therapy in Crohn's disease? A decision analysis. Inflamm Bowel Dis 2013 0.93
21 Distinct microbiome in pouchitis compared to healthy pouches in ulcerative colitis and familial adenomatous polyposis. Inflamm Bowel Dis 2010 0.92
22 Efficacy and safety of natalizumab in Crohn's disease patients treated at 6 Boston academic hospitals. Inflamm Bowel Dis 2013 0.92
23 Marijuana use patterns among patients with inflammatory bowel disease. Inflamm Bowel Dis 2013 0.92
24 Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent. Inflamm Bowel Dis 2011 0.89
25 Growth factors as treatment options for intestinal inflammation. Ann N Y Acad Sci 2006 0.86
26 Certolizumab pegol compared to natalizumab in patients with moderate to severe Crohn's disease: results of a decision analysis. Dig Dis Sci 2011 0.86
27 Barriers to enrollment in inflammatory bowel disease randomized controlled trials: an investigation of patient perspectives. Inflamm Bowel Dis 2012 0.85
28 Validation of interactive voice response system administration of the Short Inflammatory Bowel Disease Questionnaire. Inflamm Bowel Dis 2009 0.85
29 Risk Factors for Rehospitalization Within 90 Days in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis 2015 0.82
30 Immediate versus tailored prophylaxis to prevent symptomatic recurrences after surgery for ileocecal Crohn's disease? Surgery 2011 0.81
31 Strategies for the prevention of postoperative recurrence in Crohn's disease: results of a decision analysis. Am J Gastroenterol 2011 0.81
32 Selective use of selective nonsteroidal anti-inflammatory drugs in inflammatory bowel disease. Clin Gastroenterol Hepatol 2006 0.80
33 Modifiable Risk Factors for Hospital Readmission Among Patients with Inflammatory Bowel Disease in a Nationwide Database. Inflamm Bowel Dis 2017 0.77
34 Factors associated with durable response to infliximab in Crohn's disease 5 years and beyond: a multicenter international cohort. Inflamm Bowel Dis 2015 0.76
35 Crohn's Cartography: Mapping Disease Patterns and Trajectories Using the Lémann Index-Are We Finding Our Way? J Clin Gastroenterol 2016 0.75
36 Impaired innate immune function associated with fecal supernatant from Crohn's disease patients: insights into potential pathogenic role of the microbiome. Inflamm Bowel Dis 2014 0.75
37 Hospitalizations for Acute Myocardial Infarction Are Decreased Among Patients with Inflammatory Bowel Disease Using a Nationwide Inpatient Database. Inflamm Bowel Dis 2016 0.75